Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis (HOPE-1 Study: Hydration for Optimal Pulmonary Effectiveness)

NCT03229252 is registered in ClinicalTrials.gov with Spyryx Biosciences, Inc. as lead sponsor.

NCT NCT03229252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03229252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis (HOPE-1 Study: Hydration for Optimal Pulmonary Effectiveness)
Lead sponsor
Spyryx Biosciences, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2017
Completion date
June 20, 2019
Enrollment
91 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis